Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMINENT
2016-003818-26Phase 3Completed
- Sponsor
- Kowa Research Institute, Inc.
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), hypertriglyceridemia and cardiac morbidity comparing Pemafibrate with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jan 2017; status: completed.
02
Drugs
pemafibrate
03
Conditions
type 2 diabetes mellitus (T2DM)hypertriglyceridemiacardiac morbidity
Beyond the preview
Go deeper on 2016-003818-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003818-26.